Effect of empagliflozin on liver fibrosis and steatosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: a randomized clinical trial
Abstract
BACKGROUND AND AIM: Metabolic dysfunction-associated steatotic (MASLD) is a common complication in diabetic patients that can lead to fibrosis and severe liver complications. This study aimed to investigate the effect of empagliflozin on liver markers and fibrosis in diabetic patients with NAFLD. METHODS: This was a single-center, randomized, controlled, phase II clinical trial including 119 patients with type 2 diabetes and MASLD. Patients were randomized to receive either empagliflozin (10 mg or 25 mg daily) or standard care for 6 months. Liver enzymes, imaging scores (MRI and ultrasound), and fibrosis indices (FIB-4 and NFS) were assessed at baseline and at study completion. Statistical analyses included between- and within-group comparisons, adjusted models for baseline imbalances and age. RESULTS: Empagliflozin significantly reduced liver enzymes compared with controls (ALT − 41.2 vs. −4.6 IU/L; AST − 18.4 vs. −3.3 IU/L; GGT − 25.5 vs. −2.2 IU/L; all p < 0.001). The FIB-4 index decreased in the intervention group (1.20→1.06, p < 0.001) but not in controls (1.42→1.42, p = 0.233). The NAFLD fibrosis score showed no significant change. Imaging confirmed greater improvement in the empagliflozin group, with 94% showing grade 1 or lower steatosis on ultrasound and 100% achieving grade 0 on MRI (p < 0.001 for both). Importantly, complementary analyses (ANCOVA and mixed models) demonstrated that these improvements remained significant after adjustment for age and baseline…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 119 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.